| Dr Marvin Jules Stone, MD | |
|
3500 Gaston Ave, Sammons #5802, Dallas, TX 75246-2017 | |
| (214) 820-3445 | |
| (214) 820-2780 |
| Full Name | Dr Marvin Jules Stone |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 3500 Gaston Ave, Dallas, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427189992 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | D7488 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marvin Jules Stone, MD 3500 Gaston Ave, Sammons #5802, Dallas, TX 75246-2017 Ph: (214) 820-3445 | Dr Marvin Jules Stone, MD 3500 Gaston Ave, Sammons #5802, Dallas, TX 75246-2017 Ph: (214) 820-3445 |
News Archive
Like most over-the-counter products, not all sunscreens are created equal. Some sunscreens provide higher sun protection, while others contain ingredients that are better suited for children's skin. The key is choosing a sunscreen that will provide the best sun protection for all family members, and combining sunscreen use with other sun-smart behaviors.
Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms is pleased to announce that a recent research publication from Princeton University reveals the genetic basis of poly-ß-1,6-N-acetylglucosamine (PNAG), the DispersinB® enzyme substrate, based biofilm formation in bacteria.
Researchers of the TGF-beta and Cancer group of Bellvitge Biomedical Research Institute, in collaboration with King's College London, have unveiled the role of NADPH oxidase NOX4 as an inhibitor of the epithelial-amoeboid transition, a process that contributes to the migration and invasion of tumor cells.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the FDA intended to grant its recently-submitted ocriplasmin BLA (Biological License Application) for Priority Review.
› Verified 1 days ago
Uma B.r.k Pakkivenkata, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 215, Dallas, TX 75231 Phone: 214-396-4950 Fax: 877-423-5360 | |
Dr. Ariel Marcelo Modrykamien, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3600 Gaston Ave, Wadley Tower, Suite 960, Dallas, TX 75246 Phone: 402-972-6078 | |
Benjamin Seth Martinez, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3111 Fax: 214-648-5461 | |
Vijaya Mummadi, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 225, Dallas, TX 75231 Phone: 469-646-8880 Fax: 469-646-8884 | |
Dr. Ting-yi Chen, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2800 Fax: 214-645-2808 | |
William Cook Langmade, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1441 N Beckley Ave, Dallas, TX 75203 Phone: 214-947-2306 | |
Dr. Janame J Kottey, MBBS Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 13154 Coit Rd Ste 100, Dallas, TX 75240 Phone: 214-358-2300 Fax: 214-579-6989 |